{
    "clinical_study": {
        "@rank": "146166", 
        "arm_group": [
            {
                "arm_group_label": "SA09012 Low dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "SA09012 High dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial\n      Asthma Patients"
        }, 
        "brief_title": "Safety and Efficacy of SA09012 in Asthma", 
        "condition": "Mild to Moderate Bronchial Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis or presence of asthma the previous quarter of the screening visit\n\n          -  FEV1 or PEF between 60% and 85% of the predicted normal value at screening or within\n             the 3 months of the screening visit\n\n          -  Having signed an informed consent\n\n        Exclusion Criteria:\n\n          -  Patient who has severe asthma\n\n          -  Patient who has any significant medical condition that might compromise patient\n             safety, interfere with evaluation or preclude completion of the study other\n             protocol-defined inclusion/exclusion criteria may apply\n\n          -  Patient with an AST or ALT > 2x ULN (upper limit of normal) in the screening visit\n\n          -  Patient with more than 10 pack year of cigarettes history"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "234", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01740986", 
            "org_study_id": "SA09012-P2"
        }, 
        "intervention": [
            {
                "arm_group_label": "SA09012 Low dose", 
                "description": "Tablet, b.i.d", 
                "intervention_name": "SA09012 Low dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SA09012 High dose", 
                "description": "Tablet, b.i.d", 
                "intervention_name": "SA09012 High dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Tablet, b.i.d", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Asthma", 
        "lastchanged_date": "December 5, 2012", 
        "location": {
            "contact": {
                "email": "youngkim@catholic.ac.kr", 
                "last_name": "Young Kyoon Kim"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul St. Mary's Hospital of the Catholic university of Korea"
            }, 
            "investigator": {
                "last_name": "Young Kyoon Kim", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "Double Blinded, Randomized, Placebo Controlled, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial Asthma Patients", 
        "overall_contact": {
            "email": "youngkim@catholic.ac.kr", 
            "last_name": "Young Kyoon Kim"
        }, 
        "overall_official": {
            "affiliation": "Seoul ST. Mary's Hospital of the Catholic University of Korea", 
            "last_name": "Young Kyoon Kim, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean change from baseline of PEF(Peak Expiratory Flow)at week 6", 
            "safety_issue": "No", 
            "time_frame": "6 week treatment period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01740986"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean change from baseline in FEV1 at week 6", 
                "safety_issue": "No", 
                "time_frame": "6 week treatment period"
            }, 
            {
                "measure": "Mean change from baseline in ACT(Asthma Control Test) at week 6", 
                "safety_issue": "No", 
                "time_frame": "6 week treatment period"
            }, 
            {
                "measure": "Safety assessment(Comparison of the adverse event profiles throughout the course of the study)", 
                "safety_issue": "Yes", 
                "time_frame": "6 week treatment period"
            }
        ], 
        "source": "SamA Pharmaceutical Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "SamA Pharmaceutical Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}